Safety of radiofrequency ablation for reducing inflammatory cytokine levels and the left atrial diameter in patients with atrial fibrillation

Linling Zhong*, Xiaoshu Yin* and Zhihong Xie

Abstract

Objective: To investigate the safety of radiofrequency ablation for reducing inflammatory cytokines and the left atrial diameter in patients with atrial fibrillation (AF).

Methods: A total of 200 patients with AF who were admitted to our hospital from December 2015 to April 2017 were included in this prospective analysis. Fifty patients were treated with conventional AF medication alone (AF medication group) and 50 patients received radiofrequency ablation (RFA) on the basis of conventional medication (RFA group).

Results: After treatment, the AF medication group showed significantly higher levels of high-sensitivity C-reactive protein, interleukin-6, carboxyterminal propeptide of type-I procollagen, procollagen type III N-terminal propeptide, and matrix metallopeptidase-9 than the RFA group. The AF medication group had a significantly lower activated partial thromboplastin time, thrombin time, and prothrombin time than the RFA group. A significantly smaller left atrial diameter was observed in both groups after treatment, but this decrease was more pronounced in the RFA group than in the AF medication group. The total treatment efficacy rate was significantly lower in the AF medication group than in the RFA group.

Conclusions: For patients with AF, RFA leads to a lower incidence of inflammatory responses, faster recovery of cardiac function, and good safety.

Keywords

Atrial fibrillation, radiofrequency ablation, safety, cytokine, left atrial diameter, inflammatory response, thrombin time

*These authors contributed equally to this work.

Corresponding author:

Zhihong Xie, Department of Cardiology, People’s Hospital of Ganzhou, No. 16 Meiguan Avenue, Zhanggong District, Ganzhou, Jiangxi 341000, China.

Email: zhihongxie0905@163.com
**Introduction**

Atrial fibrillation (AF) is the most common irregular heart rhythm that starts in the atria and usually occurs in the presence of organic heart disease. The prevalence of AF increases with age, and middle-aged and older patients are the fastest growing population subsets.\(^1\) Although AF is typically associated with age and underlying diseases of aging, constantly changing living standards and habits have led to an increase in morbidity of heart disease in the younger population.\(^2\) Statistical data have shown that among patients with similar underlying diseases, patients with AF have a higher risk of death and poorer prognosis.\(^3\) The treatment options for AF have undergone continuous improvement in terms of efficacy owing to the increasing number of new medical technologies and in-depth research knowledge, but issues, such as a high recurrence rate and the incidence of adverse reactions, persist. Additionally, patients without timely and effective treatment are more vulnerable to heart failure and sudden death.\(^4,5\) Therefore, the need to develop efficacious and safe treatment methods for AF is particularly urgent.

As reported in the clinical literature, pulmonary vein isolation is pivotal in radiofrequency ablation (RFA) to reduce signs and symptoms in patients with AF.\(^6\) However, RFA may lead to recurrence of AF and is usually performed under sedation and in surgical conditions. The long immobilization time of RFA can weaken the patients' autonomous ventilation. Therefore, intervention is required to maintain the patient's airways together with deep sedation. Unstable breathing and hemodynamics caused by excessive sedation affect the pulmonary veins and left atrium, and extend the ablation time.\(^7\)–\(^9\) Nevertheless, this treatment has the advantages of leaving a small wound, a fast recovery rate, and a generally high success rate. Therefore, RFA is commonly used for treating patients with AF.\(^10\) This study aimed to examine the therapeutic effect of RFA from the perspective of the inflammatory response and recovery of normal heart function to improve application of this treatment in clinical practice.

**Materials and methods**

**Patient population**

A total of 100 patients with AF who were admitted to our hospital from December 2015 to April 2017 were included in this study for prospective analysis. Among these patients, 80 had hypertension, 35 had diabetes, and 52 had hyperlipidemia. One group (\(n = 50\)) of patients was treated with conventional AF medication alone (AF medication group) and the other group (\(n = 50\)) received RFA on the basis of conventional medication (RFA group).

**Inclusion and exclusion criteria**

Patients with AF who were admitted to our hospital and met the criteria listed in the Guidelines for Management of Patients with AF\(^11\) and those with typical signs and symptoms of AF observed on electrocardiography (ECG) 3 months before admission were enrolled in this study. We excluded patients with a history of the following: congenital heart disease and heart valve or other heart diseases; parenchymal diseases or diseases of other organs; diseases, such as thyroid, blood, and immune system diseases; liver and kidney injuries; and poor compliance.

Informed consent was signed and provided by all of the patients and their families. The study protocol was approved by the People's Hospital of Ganzhou Ethics Committee (Ganzhou, China) in August 2015. The trial registration number is NCT01998654.
Reagents and materials

Heparin was purchased from Guangzhou Yangye Biotechnology Co., Ltd. (Guangzhou, China). Three-dimensional electroanatomical mapping systems were obtained from Johnson & Johnson (New Brunswick, NJ, USA). The M5 Color Doppler Ultrasonic Diagnostic Instrument was acquired from BELSE (Xuzhou, China). The TLC5000 12-lead Dynamic ECG System was from Heal Force (Shanghai, China). Enzyme-linked immunosorbent assay kits were purchased from Shanghai Qincheng Biotechnology Co., Ltd. (Shanghai, China). The automatic biochemical analyzer was from LICA United Technologies Limited (Beijing, China).

RFA

The AF medication group was administered drugs that restored sinus rhythm. The RFA group underwent RFA, while also following the same medication regime as the AF medication group. Disinfection and local anesthesia were performed after the surgical field was covered with a sterile surgical towel before surgery. Using a needle, the surgeon punctured the right femoral vein site and guided the needle into a transseptal access sheath to complete transseptal atrial puncture. After transseptal puncture of the interatrial septum, 5000 U of intravenous heparin was administered. Imaging and three-dimensional model reconstruction of the left atrium and pulmonary veins were then performed. Pulmonary vein isolation was completed at 30 W and 45°C. The end point of RFA was potential disappearance of the pulmonary vein, which indicated that bidirectional conduction block had been achieved. For patients with unsatisfactory outcomes, additional potential ablation was contingent to specific conditions. Otherwise, further medication and current stimulation were required. The treatment efficacy and complications were evaluated at 3 and 6 months after surgery. Cardiac ultrasonography, 24-hour dynamic ECG, and conventional ECG were regularly reviewed.

Detection of cardiac and biochemical indicators

All of the patients underwent color Doppler echocardiography in the lateral or supine position before and at 3 days after treatment to measure the left atrial diameter (LAD). The probe used a frequency ranging from 2.0 to 3.5 MHz. Twelve-lead dynamic ECG was initiated with an electrode placement on specific positions for 24-hour observation. Before and at 3 days after treatment, P waves were recorded and analyzed in three consecutive cardiac cycles to identify the minimum (Pmin) and maximum (Pmax) P-wave durations and to calculate P-wave dispersion (Pd), which was defined as the difference between Pmin and Pmax. Coagulation parameters, including the thrombin time (TT), activated partial thromboplastin time (APTT), and prothrombin time (PT), were measured using an automated biochemical analyzer. Double-antibody enzyme-linked immunosorbent assay was performed according to the kit instructions to determine the levels of matrix metallopeptidase-9 (MMP-9), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), carboxyterminal propeptide of type-I procollagen (PICP), and procollagen type III N-terminal propeptide (PIIINP).

Observational indicators

We investigated the LAD and ECG, inflammatory cytokine levels, blood coagulation, myocardial fibrosis, and the incidence of adverse reactions (i.e., possible complications after invasive surgery). Six months after surgery, we also determined the
treatment efficacy. High efficacy was considered when there was significantly reduced symptomatic AF and atrial flutter, good efficacy when there was slightly relieved symptomatic AF and atrial flutter, and no efficacy when there were continuing symptoms with no improvement.12

**Statistical analysis**

Statistical analysis was performed using SPSS Statistics version 19.0 (Beijing NDTimes Science and Technology Co., Ltd., Beijing, China). The data of the two groups are expressed as mean ± standard deviation. Comparison of adverse reactions and clinical efficacy between the groups was made using the chi-square test. Other data of the two groups were compared by the t test and data observed before and after treatment in the same group were subjected to the paired t test. The results were plotted in GraphPad Prism 8 (San Diego, CA, USA), and we assumed statistical significance if the P value was <0.05.

**Results**

**General characteristics**

We included 55 men and 45 women with a mean age of 62.50 ± 14.47 years. We found no significant differences in sex, age, AF type, and the disease course between the two groups (Table 1).

**Inflammatory cytokine levels and coagulation after treatment**

The RFA group showed significantly lower levels of hs-CRP and IL-6 than the AF medication group after treatment (both P <0.001; Table 2). The APTT, TT, and PT were significantly higher in the RFA group than in the AF medication group (all P <0.001; Table 3).

| Table 1. Comparison of general characteristics between the groups. |
|---------------------------------------------------------------|
|                  | AF medication group (n = 50) | RFA group (n = 50) | \( \chi^2/t \) | P |
|------------------|-----------------------------|-------------------|----------------|---|
| Sex (n, %)       |                             |                   | 0.040          | 0.841 |
| Male             | 27 (54.00)                  | 28 (56.00)        |                |     |
| Female           | 23 (46.00)                  | 22 (44.00)        |                |     |
| Age (years)      | 62.24 ± 14.36               | 61.89 ± 14.53     | 0.121          | 0.904 |
| Hypertension (n, %) |                       |                   | 0.250          | 0.617 |
| Yes              | 41 (82.00)                  | 39 (78.00)        |                |     |
| No               | 9 (18.00)                   | 11 (22.00)        |                |     |
| Diabetes (n, %)  |                             |                   | 0.396          | 0.529 |
| Yes              | 19 (38.00)                  | 16 (32.00)        |                |     |
| No               | 31 (62.00)                  | 34 (68.00)        |                |     |
| Hyperlipidemia (n, %) |                       |                   | 0.160          | 0.689 |
| Yes              | 25 (50.00)                  | 27 (54.00)        |                |     |
| No               | 25 (50.00)                  | 23 (46.00)        |                |     |
| Types of AF (n, %) |                           |                   | 0.053          | 0.817 |
| Paroxysmal AF (n, %) | 37 (74.00)              | 38 (76.00)        |                |     |
| Persistent AF (n, %) | 13 (26.00)              | 12 (24.00)        |                |     |
| Course of disease (months) | 10.53 ± 3.25      | 10.84 ± 3.18     | 0.482          | 0.631 |
| Homocysteine (μmol/L) | 14.64 ± 4.63         | 14.68 ± 4.59     | 0.043          | 0.966 |

Values are mean ± standard deviation or n (%). AF, atrial fibrillation; RFA, radiofrequency ablation.
Myocardial fibrosis markers and LAD after treatment

The RFA group had significantly lower PICP, PIIINP, and MMP-9 levels than the AF medication group after treatment (all \( P < 0.001 \); Table 4). The LAD was not significantly different between the two groups before treatment. However, the LAD was significantly larger in the AF medication group than in the RFA group after treatment (\( P < 0.05 \)), despite the significant treatment-related decrease in both groups (both \( P < 0.05 \); Figure 1).

**ECG findings**

No significant differences in ECG findings were found between the two groups before treatment. However, Pmax, Pmin, and Pd were significantly higher in the AF medication group than in the RFA group after treatment (all \( P < 0.05 \)). Treatment led to a significant decrease in these parameters in both groups (all \( P < 0.05 \); Figure 2).

**Adverse reactions and clinical efficacy**

The AF medication group appeared to have a higher incidence of dizziness, palpitations, chest pain, and shortness of breath, but a
lower incidence of local hemorrhage and thrombosis than the RFA group. However, the total incidence of adverse reactions was not significantly different between the groups (Table 5). The RFA group had a significantly higher total treatment efficacy rate than the AF medication group (P = 0.046; Table 6).

Discussion

AF is an arrhythmia characterized by grossly disorganized atrial electrical activity. When AF occurs, an irregular atrial rhythm can be observed on ECG, forming a rapid, disordered wave that triggers atrial pump dysfunction by affecting the regular cardiac cycle (systole and diastole). Pump dysfunction may result in hemodynamic changes and higher rates of embolization, disability, and mortality.13,14 With chronic symptoms of AF, a weakened electrical conduction that travels from the atrioventricular node to the atria is likely and initiates an irregular ventricular contraction frequency, thus increasing the difficulty of treatment of AF.15 AF induces dizziness, chest tightness, palpitations, and other clinical symptoms. Symptoms of AF are latent at an early stage and may include heart failure, sudden death, and other dangerous conditions with an increasing rate and rhythm of AF.16,17 The rationale behind the existing therapies for AF is to restore sinus rhythm and regulate the rate of AF.18,19 RFA, which is a simple, effective, and safe treatment option for AF, is commonly used as the first-line treatment of persistent AF.20 In RFA, a catheter with an electrode in its tip is guided through the veins or arteries, and the radiofrequency current is passed through the electrode onto the problem area of the cardiac chambers. This exposes the local endocardium and myocardium to coagulative necrosis, with the ultimate aim of blocking arrhythmia conduction tracts at their points of origin.21,22 In view of the role of RFA in AF treatment, we examined inflammatory responses, cardiac function, safety, and efficacy after applying this technique in patients with AF.

Our study showed that hs-CRP and IL-6 concentrations were significantly higher in the AF medication group than in the RFA group after treatment. High inflammatory cytokine levels were previously reported to be negatively correlated with ultra-structure recovery of atrial myocytes and even with the atrial electrical system.23 Our findings indicated that in the patients who underwent RFA, the inflammatory responses that followed after recovery of surgical wounds had a low incidence in contrast to those in patients who received drug treatment only. Consequently, this was more favorable for intra-atrial conduction.

With regard to blood coagulation, the AF medication group showed a significantly lower APTT, TT, and PT than the RFA group. Previous studies have suggested that appropriate anticoagulation in AF
treatment may reduce the incidence of complications, such as thrombosis and embolism, improve hemorheology, and increase efficacy. These studies also proposed that anticoagulation might be considered after RFA for patients with AF. With regard to myocardial fibrosis, we found that PICP, PIIINP, and MMP-9 levels in the AF

Table 5. Comparison of adverse reactions.

|                  | AF medication group (n = 50) | RFA group (n = 50) | \( \chi^2 \) | P       |
|------------------|-----------------------------|-------------------|------------|---------|
| Dizziness        | 3 (6.00)                    | 1 (2.00)          | –          | –       |
| Palpitations and chest pain | 4 (8.00)                   | 2 (4.00)          | –          | –       |
| Shortness of breath | 2 (4.00)                   | 1 (2.00)          | –          | –       |
| Local hemorrhage | 0                           | 1 (2.00)          | –          | –       |
| Thrombosis       | 2 (4.00)                    | 3 (6.00)          | –          | –       |
| Incidence of adverse reactions | 11 (22.00)               | 8 (6.00)          | 0.585      | 0.444   |

Values are n (%). AF, atrial fibrillation; RFA, radiofrequency ablation.
medication group were significantly higher than those in the RFA group. According to previous studies\textsuperscript{25,26} inflammation, oxidative stress, and signaling pathways cause atrial fibrosis, which forms the basis of pathological changes in AF. This leads to electrical and structural remodeling of the left atrium and uneven electrical activity. In the present study, apart from decreasing the inflammatory response and recovering blood coagulation, RFA was also an intervention therapy for cardiac fibrosis in reducing the pathological factors of AF. Further analysis of cardiac function showed that after treatment, the LAD was significantly decreased in both groups, but this decrease was more significant in the RFA group. These results were similar for \(P_{\text{max}}, P_{\text{min}},\) and \(P_d\) values. These findings indicated a smaller LAD and an almost normal heart beat frequency after RFA. Release of inflammatory mediators results in endocardial damage, increased blood viscosity and thrombus, and a larger atrial inner diameter, which ultimately leads to atrial structural remodeling, myocardial edema, and myocardial fibrosis\textsuperscript{27,28} Moreover, P-wave monitoring enables analysis of changes during arrhythmia and thus provides a reliable basis for diagnosis and treatment of AF, with the duration of the P-wave duration indicating changes in atrial diameter.\textsuperscript{29} Therefore, ECG and the LAD can be used to predict the inflammatory response and blood viscosity in the body. Recovery of cardiac function is better with a smaller atrial diameter.

Our study also showed that the AF medication group had higher incidence rates of dizziness, palpitations, chest pain, and shortness of breath, but lower incidence rates of local hemorrhage and thrombosis than the RFA group after treatment. However, there was no significant difference in the total incidence of adverse reactions between the two groups. The RFA group also showed a significantly higher total efficacy rate than the AF medication group. Drug-based RFA in patients with AF, despite the surgical risks, lowered the total incidence rates of postoperative complications, reduced the incidence of existing complications, and showed higher safety and efficacy compared with medication alone. RFA is a commonly used minimally invasive interventional therapy strategy with high efficacy for patients with AF.\textsuperscript{30} However, RFA also exposes patients to surgical risks owing to vascular puncture, catheter manipulation, and discharge for ablation. Besides being consistent with previous findings, our findings further confirm the safe application of RFA, despite known risks.

This study has some limitations. We did not perform detailed deviation calculations for collection of the sample size. The limited sample size may have affected statistical differences of our data. Additionally, there was a lack of detailed comparisons of adverse reactions based on different variables within the RFA group. More detailed analysis of adverse reactions may lead to improved safety and better therapy.

**Table 6.** Comparison of clinical efficacy between the groups.

|                     | AF medication group (n = 50) | RFA group (n = 50) | \(\chi^2\) | P  |
|---------------------|------------------------------|-------------------|----------|----|
| High efficacy       | 22 (44.00)                   | 29 (58.00)        | –        | –  |
| Good efficacy       | 20 (40.00)                   | 19 (38.00)        | –        | –  |
| No efficacy         | 8 (16.00)                    | 2 (4.00)          | –        | –  |
| Total efficacy rate | 42 (84.00)                   | 48 (96.00)        | 4.000    | 0.046 |

Values are n (%). AF, atrial fibrillation; RFA, radiofrequency ablation.
outcomes in the application of RFA in treatment for AF.

**Conclusions**
For patients with AF, RFA is a technique with good safety and efficacy, and it reduces inflammation, particularly in cardiac function. Our study provides reliable data for surgical selection of patients with AF. Patients with AF should consider the safety of treatment when undergoing invasive treatment.

**Declaration of conflicting interest**
The authors declare that there is no conflict of interest.

**Funding**
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**ORCID iD**
Zhihong Xie https://orcid.org/0000-0001-8364-3412

**References**

1. Celikyurt U, Knecht S, Kuehne M, et al. Incidence of new-onset atrial fibrillation after cavotricuspid isthmus ablation for atrial flutter. *Europace* 2017; 19: 1776–1780. DOI: 10.1093/europace/euw343.

2. Yang PS, Ryu S, Kim D, et al. Variations of prevalence and incidence of atrial fibrillation and oral anticoagulation rate according to different analysis approaches. *Sci Rep* 2018; 8: 6856. DOI: 10.1038/s41598-018-25111-6.

3. Sartipy U, Savarese G, Dahlstrom U, et al. Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. *Eur J Heart Fail* 2019; 21: 471–479. DOI: 10.1002/ejhf.1389.

4. Steinberg BA, Gao H, Shrader P, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. *Am Heart J* 2017; 194: 132–140. DOI: 10.1016/j.ahj.2017.08.011.

5. Nagashima K, Okumura Y, Watanabe I, et al. Hot balloon versus cryoballoon ablation for atrial fibrillation: lesion characteristics and middle-term outcomes. *Circ Arrhythm Electrophysiol* 2018; 11: e005861. DOI: 10.1161/CIRCEP.117.005861.

6. Lackermair K, Clauss S, Voigt T, et al. Alteration of endothelin 1, MCP-1 and chromogranin A in patients with atrial fibrillation undergoing pulmonary vein isolation. *PLoS One* 2017; 12: e0184337. DOI: 10.1371/journal.pone.0184337.

7. Kim HJ, Park BK and Chung IS. Comparison of general anesthesia and conscious sedation during computed tomography-guided radiofrequency ablation of T1a renal cell carcinoma. *Can Assoc Radiol J* 2018; 69: 24–29. DOI: 10.1016/j.carj.2017.07.003.

8. Dong Y, Zhang S, Gao L, et al. Impact of pulmonary vein isolation on atrial vagal activity and atrial electrical remodeling. *J Geriatr Cardiol* 2008; 5: 28–32.

9. Katritsis D, Wood MA, Giazitzoglou E, et al. Long-term follow-up after radiofrequency catheter ablation for atrial fibrillation. *Europace* 2008; 10: 419–424.

10. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. *JAMA* 2005; 293: 2634–2640.

11. Cai PY, Derequito R, Mishra M, et al. A non-surgeon’s guide to surgical management of atrial fibrillation. *J Surg (Northborough)* 2013; 1: 1000010.

12. Gudkov AV. Experience of long-term afala treatment in benign prostatic hyperplasia. *Bull Exp Biol Med* 2009; 148: 308–311.

13. Olbers J, Jacobson E, Viberg F, et al. Systolic blood pressure increases in patients with atrial fibrillation regaining sinus rhythm after electrical cardioversion. *J Clin Hypertens (Greenwich)* 2019; 21: 363–368. DOI: 10.1111/jch.13496.
14. Orgel R, Wojdyla D, Huberman D, et al. Noncentral nervous system systemic embolism in patients with atrial fibrillation: results from ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Circ Cardiovasc Qual Outcomes 2017; 10: e003520. DOI: 10.1161/CIRCOUTCOMES.116.003520.

15. Sun YL, Li PH, Shi L, et al. Valsartan reduced the vulnerability to atrial fibrillation by preventing action potential prolongation and conduction slowing in castrated male mice. J Cardiovasc Electrophysiol 2018; 29: 1436–1443.

16. Mitamura H. [Pathophysiology and clinical manifestations of atrial fibrillation]. Nihon Rinsho 2013; 71: 23–28.

17. Reinier K, Marijon E, Uy-Evanado A, et al. The association between atrial fibrillation and sudden cardiac death: the relevance of heart failure. JACC Heart Fail 2014; 2: 221–227.

18. Imai Y, Yokoyama Y and Watanabe T. Sinus node recovery time can predict maintenance of sinus rhythm after catheter ablation for long-standing atrial fibrillation. Int Heart J 2018; 59: 460–461.

19. Wattanasuwan N, Khan IA, Mehta NJ, et al. Acute ventricular rate control in atrial fibrillation: IV combination of diltiazem and digoxin vs. IV diltiazem alone. Chest 2001; 119: 502–506. DOI: 10.1378/chest.119.2.502.

20. Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 2014; 311: 692–700. DOI: 10.1001/jama.2014.467.

21. Ho SY and McCarthy KP. Anatomy of the left atrium for interventional electrophysiologists. Pacing Clin Electrophysiol 2010; 33: 620–627. DOI: 10.1111/j.1540-8159.2009.02659.x.

22. Kaba RA, Cannie D and Ahmed O. RAAFT-2: radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation. Glob Cardiol Sci Pract 2014; 2014: 53–55. DOI: 10.5339/gscp.2014.26.

23. Kim N, Jung Y, Nam M, et al. Angiotensin II affects inflammation mechanisms via AMPK-related signalling pathways in HL-1 atrial myocytes. Sci Rep 2017; 7: 10328. DOI: 10.1038/s41598-017-09675-3.

24. Goette A. Uninterrupted NOAC therapy in patients undergoing catheter ablation of atrial fibrillation: “dual anticoagulant therapy” ready for primetime or systematic overtreatment? Int J Cardiol 2018; 270: 185–186.

25. Fu XX, Zhao N, Dong Q, et al. Interleukin-17A contributes to the development of postoperative atrial fibrillation by regulating inflammation and fibrosis in rats with sterile pericarditis. Int J Mol Med 2015; 36: 83–92. DOI: 10.3892/ijmm.2015.2204.

26. Talman V and Ruskoaho H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res 2016; 365: 563–581. DOI: 10.1007/s00441-016-2431-9.

27. Rosianu SH, Rosianu AN, Aldica M, et al. Inflammatory markers in paroxysmal atrial fibrillation and the protective role of renin-angiotensin-aldosterone system inhibitors. Clujul Med 2013; 86: 217–221.

28. Zhang XY, Yu RH and Dong JZ. Clinical characteristics and efficacy of radiofrequency catheter ablation in the treatment of elderly patients with atrial fibrillation. Am J Med Sci 2018; 355: 357–361.

29. Yilmaz M, Altın C, Tekin A, et al. Assessment of atrial fibrillation and ventricular arrhythmia risk after bariatric surgery by P wave/QT interval dispersion. Obes Surg 2017; 28: 932–938.

30. Berger WR, Meulendijks ER, Limpens J, et al. Persistent atrial fibrillation: A systematic review and meta-analysis of invasive strategies. Int J Cardiol 2019; 278: 137–143.